Facebook
X
LinkedIn
ForwardA Randomized Study of Consolidation Chemoradiation (CTRT) versus Observation after first line chemotherapy (CT) in Advanced Gall Bladder Cancers (GBC): Race-GB Study
Management of unresectable gall bladder cancer (GBC) is challenging, and it can be especially so in Low-to-Middle Income Countries (LMIC), as <50% of patients complete the standard 6 cycles of CT. This article presents the results of a single center, open label, randomized trial evaluating consolidation chemoradiation (CTRT) versus observation in a LMIC center for patients with unresectable gall bladder cancer (GBC) who completed and responded to 4 cycles of chemotherapy. The endpoint was overall survival (OS).
A total of 135 patients were randomized into two groups (67 – observation, 68 – CTRT). RT consisted of 3DRT to the GBC and lymphatics (45Gy in 25fx), followed by a boost to GBC (9Gy in 5fx). The actual median OS from the time of
recruitment was 7 months (95%CI 6.114 to 7.88) in the observation arm versus 13 months (95% CI 11.13 months to 14.84 months) in the CTRT arm.
Please visit https://www.redjournal.org/article/S0360-3016(24)03706-4/fulltext to read the related journal article online.
This activity is available from April 14, 2025, through 11:59 p.m. Eastern time on April 13, 2027.
This article is from the May 2025 issue of the International Journal of Radiation Oncology•Biology•Physics (Red Journal).
Target Audience
This course is designed to meet the interest of radiation oncologists and radiation oncology residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the additional challenges for treatment of unresectable gall bladder cancers (GBC) in low-to-middle income countries (LMIC).
- Summarize the results of a randomized trial (single center, LMIC) evaluating consolidation chemoradiation versus observation for patients with unresectable GBC with overall survival as the endpoint.
Course summary
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sue Yom, MD, PhD, FASTRO is employed by the University of California and receives compensation from Bristol-Myers Squibb, EMD Serono, Nanobiotx and Elsevier as well as ownership/investment in Springer and Up To Date.
The person(s) above served as the developer(s) of this activity. Additionally, ASTRO Education Committee had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Activity Fees
This activity is included in the ASTRO Academy Subscription. To purchase the subscription beginning December 1, 2026, please go to the ASTRO Product Catalog.
ASTRO members and Academy subscribers must log in to the ASTRO Academy to view and receive the corresponding rate:
- Academy Subscriber: $0
- Member: $0
- Member-in-Training / Student Member / Postdoctoral Fellow Member: $0
- Nonmember: $49
Discounts
Please email ASTRO eLearning to inquire about the discounts below.
- If you are an ASTRO member residing in a low- or lower-middle-income economy country, as identified by the World Bank, you can receive a 50% discount off the activity fee.
- If you are an ASTRO member residing in an upper-middle-income economy country, as identified by the World Bank, you can receive a 25% discount off the activity fee.
Policies
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until the Activity expiration date, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Copyright of all aspects of ASTRO Academy Content, including recordings and/or reproductions of sessions, programs, presentations, discussions and other scheduled events (“ASTRO Academy Content”) is owned by ASTRO. Only ASTRO reserves the rights to all ASTRO Academy Content, including to digitize, modify, alter, edit, adapt, create derivative works, display, publicly perform, exhibit, transmit, broadcast, reproduce, exploit, sell, rent license, otherwise use, and permit others to use, such ASTRO Academy Content. Photographing, filming, taping, recording or any form of capture or reproduction in any medium of any aspect of ASTRO Academy Content, including, but not limited to the programs, presentations, material, sessions, and discussions, or on the Academy platform are strictly forbidden without written authorization from ASTRO.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.